Gene expression changes within the Hippo pathway were found to be associated with large tumor size and metastasis in breast cancer. The combined effect of genetic variants in genes of this pathway may have a causal role in breast cancer development. We examined 7086 SNPs that were not highly correlated (r 2 < 0.8) in 35 Hippo pathway genes using data from the genome-wide association study of breast cancer from the Root Consortium, which includes 3686 participants of 
The Hippo pathway is an evolutionarily conserved regulator of tissue growth and cell fate during development and regeneration. 1 Mutation and deregulation for a subset of Hippo pathway genes have been reported in several malignancies, including breast cancer. 2 Functional studies indicate that repression of this pathway causes uncontrolled cell proliferation and dramatic tissue overgrowth, which are central to carcinogenesis. 1 There are multiple important components of the Hippo pathway, including serine/threonine kinase 4 (STK4) and STK3, large tumor suppressor 1 (LATS1) and LATS2, together with the adaptor proteins Salvador homologue 1 (SAV1), MOB kinase activator 1A (MOB1A) and MOB1B. 1 This pathway has two key downstream effector proteins, Yes-associated protein (YAP, encoded by YAP1) and transcriptional co-activator with PDZ-binding motif (TAZ, encoded by WWTR1), 3 both of which are overexpressed in breast cancer, 2 especially in triple negative breast cancer. 4 A few studies have examined the risk of breast cancer associated with genetic variations in the Hippo pathway. [5] [6] [7] Single nucleotide polymorphisms (SNPs) in YAP1 and STK4 have been reported to be associated with breast cancer risk in Chinese and European populations, respectively. 5, 6 A study conducted in African Americans reported a significant association of the whole pathway with estrogen receptor negative (ER−) breast cancer, and it revealed that CDH1 was responsible for the pathway association. 7 E-cadherin, encoded by CDH1, can function as an upstream regulatory element in the Hippo signaling pathway in mammalian cells. 1, 8 Genetic polymorphisms in CDH1 have also been reported to be associated with breast cancer susceptibility among Chinese Han women, 9, 10 but no association with lobular cancer was found in a large dataset of European population with 6023 cases and 34 271 controls. A noticeable limitation of previous studies is that only polymorphisms in a single candidate gene or a small subset of genes in this pathway were assessed, while some core elements of this pathway, such as LATS1/2, were omitted. 1, 7 Furthermore, in addition to single-SNP association analysis, it has been suggested that examining a group of SNPs within a biological pathway can provide complementary and valuable insights for the genetic architecture of complex diseases. 11, 12 Considering the paucity of data on the genomic basis of disparities in breast cancer outcomes for women of African ancestry and the growing importance of Hippo pathway in breast carcinogenesis, 13 we sought to explore whether this pathway contributes to the aggressive breast cancer phenotypes observed in women of African ancestry.
2 | METHODS
| Study participants, SNP genotyping, and imputation
The study populations of The Root Consortium have been described previously. [14] [15] [16] [17] [18] [19] [20] genes) based on Bonferroni multiple testing correction.
The single-SNP association tests, required as input for the AdaJoint test, were performed for each SNP in genes with nominal P < 0.05. We used logistic regression with case status as outcome under an additive model for genotype, adjusting for age (10-year groups), study site and the first four eigenvectors from PCA using SNPtest. 25 The first four eigenvectors were used to control for population stratification, as only the first four eigenvectors were associated with case status. 20 We corrected for multiple testing with a
Bonferroni adjustment for the effective number of independent SNPs included in the final analysis using Gao's SimpleM approach, 26 and the threshold was set at 0.05/7086 = 7.06E-06. We also calculated P adj by multiplying the original P value with 7086 to make the results more straightforward.
| Sensitivity analysis
Four genes with pathway-level P ≤ 0.05 were excluded from AdaJoint analysis one by one to test their individual contribution in the whole Hippo way. We also excluded the 2nd, 3th, and 4th genes with the smallest P values together to examine their combined effect to the whole pathway.
| Genotype and gene expression correlation
According to the estimated genetic ancestry, 27 we grouped TCGA breast cancer patients into genomic Black (≥ 50% African ancestry), genomic White (≥ 90% European ancestry), and genomic Asian (≥ 90%
Asian ancestry). We imputed The Cancer Genome Atlas (TCGA) breast cancer germline genotypes by IMPUTE2 using the 1000 Genome 
| RESULTS
Using our unique population of African ancestry that is enriched for women with early age of onset for breast cancer, analysis of germline genetic variations in the Hippo pathway at the gene level did not show a significant association for any gene with overall breast cancer risk or ER− breast cancer, as none of the variants or their combined effect achieved nominal significance (Table 1 ). However, their combined effect was significantly associated with ER+ breast cancer (pathwaylevel P = 0.019). Four of the 35 genes in this pathway, WWC1, LATS2, SCRIB, and CDH1, were associated with risk of ER+ breast cancer at nominal significance. After Bonferroni adjustment, only WWC1 gene remained statistically significant (P adj = 0.04), while the LATS2 gene showed a trend toward significance (P adj = 0.07). When WWC1 was removed from the analysis, the pathway-level significance of the assessed germline genetic variations was lost (P = 0.12). It is possible that in addition to WWC1, the major driver, there might be other genes in the Hippo pathway contributing to the association with breast cancer risk. We performed additional analyses excluding CDH1, LATS2,
and SCRIB individually or all three together, while keeping WWC1. The P values for the whole Hippo pathway turned out to be 0.075, 0.092, 0.017, and 0.086, respectively. In each analysis the top gene with the most significant P value was consistently WWC1. For each candidate gene, its start and end chromosomal positions ±10 kb were determined using the UCSC Genome Browser. SNPs within each gene region were extracted from The Root Consortium GWAS data and defined as "total SNPs." "effective number of SNPs" means the number of SNPs after excluding the SNPs with MAF < 0.01 and the SNPs with a lower MAF in every pair of SNPs with correlation r 2 ≥ 0.8. b Only P value for WWC1 remained significant after Bonferroni correction. The adjusted P values for WWC1, LATS2, and SCRIB were 0.035, 0.07, and 0.70, respectively. All other adjusted P values were equal to 1. Table S1 ). In addition, the allele frequencies between ER+ and ER− patients were significantly different for rs7344336 (P = 0.019), while the difference was marginally significant for rs147106204 (P = 0.056).
Except for rs147106204, no SNP was significantly associated with breast cancer risk after Bonferroni correction (P adj > 0.05), and no eQTL information was available for rs147106204, rs73443365, and their tagged SNPs. Additional information on the SNPs with strongest associations in other non-significant genes is listed in Supplementary   Table S2 . By investigating the genotype and gene expression data from TCGA genomic Black breast cancer patients, we found that in the Total group (ER− and ER+ combined), the expression level of WWC1 was significantly higher in AA genotype compared with CC and CA of rs147106204, which was the most significant SNP in WWC1 (Supplementary Figure S2 ). In addition, this trend was consistent in ER− and ER+ groups as well. We did not find a clear genotype-gene expression correlation across different genotypes of LATS2 rs73443365.
| DISCUSSION
In this relatively large case-control study of women of African ancestry, we found that the combined effect of genetic variations in the Hippo pathway was significantly associated with ER+ breast cancer (P = 0.019). The association was driven primarily by variants in the WWC1 LATS2, and CDH1 genes. Six highly correlated SNPs within WWC1, rs147106204, rs116516633, rs114420099, rs115567889, rs77480437, and rs114592296 were significantly associated with ER+ breast cancer risk at the SNP level.
The protein WW and C2 domain containing 1 (WWC1), also called KIBRA (expression enriched in kidney and brain), 30 interacts with and stimulates the phosphorylation of LATS1/2 and regulates the phosphorylation of YAP. WWC1 functions as a growth suppressive protein, and a study has reported that WWC1 knockdown enhanced | 1315 migration and invasion by immortalized breast epithelial cells. 31 We found a significant variant rs147106204 that tags other SNPs that overlap two transcription regulatory marks (enhancers) in breast variant human mammary epithelial cells and breast myoepithelial primary cells (Supplemental Table S1 ). We also discovered that LATS2 approached a significant association with the development of ER+ breast cancer (P adj = 0.07). At the SNP-level, LATS2 was associated with ER+ breast cancer risk, although the top SNP rs73443365 in this gene became non-significant after Bonferroni correction. LATS2 (also known as KPM), which encodes a serine/threonine protein kinase of the LATS tumor suppressor family and core protein of the Hippo pathway, is down-regulated in many types of cancers including breast cancer. 32 The reduced expression of LATS1/2 has been consistently associated with a biologically aggressive phenotype of breast cancer. 32, 33 This indicates that a partial loss of function of these tumor suppressor genes may lead to accelerated cell proliferation, resulting in an increased occurrence of aggressive disease. Given that the mechanisms by which the Hippo pathway becomes dysregulated are still not fully understood, 34 our result from a genetic association study might help to narrow down potential functional elements in the Hippo pathway components, such as WWC1 and LATS2.
It is worthy noting that the associations between the WWC1 and LATS2 genes and breast cancer risk were mainly found in ER+ participants. There might be synergistic effects between WWC1, LATS2, and estrogen receptor. 35, 36 The positive synergistic effects between these genes and ER might provide an uncommon opportunity to detect a larger association, whereas it would be challenging to detect a relatively small association attributing only to genes without the interaction with ER. Thus, if the risk factors have positive synergistic effects with ER, it may be more likely to find the associations in ER+ participant. In addition, although the result was not significant in ER− patients, it is possible that this association also exists in ER− patients and the non-significant result in our study could be explained by the difference in effect size and sample size between Figure S2) .
We were not able to compare our association findings in WWC1 and LATS2 with the previous study in African Americans because these two genes were not included in their custom genotyping assay design. 7 In that study, CDH1 was found to be nominally associated with ER− breast cancer risk, and approached the borderline of significance for association with ER + breast cancer risk, while we obtained a marginal significance with ER+ breast cancer risk. None of these associations survived multiple-testing adjustment. However, in the present study, the pathway-level P value became non-significant after excluding CDH1, which indicated that CDH1 might be one of the driver genes in the Hippo pathway.
We also searched the GAME-ON (Genetic Associations and Table S1 ) to test whether the associations reported in our study can be replicated in European populations. However, all of these SNPs are absent there. In GAME-ON/DRIVE, both the WWC1 and LATS2 genes contain different SNPs that are associated with breast cancer risks. Overall, the correlations between the significant SNPs in our study and those in the GAME-ON/DRIVE were very low (r 2 < 0.1). Actually, it is common to identify different disease-associated index SNPs between European-and African-descent populations, and this phenomenon has been frequently reported in diseases including prostate cancer [37] [38] [39] [40] and breast cancer. 7, 14, 15, 41 This inconsistency of association may be due to the different genetic backgrounds, such as LD patterns between African and European ancestries. In addition, although we undertook our GWAS using dense genotyping array with ∼2.5 million markers and imputation using the 1000 Genomes Project data, it is worth noting that rare variants (especially very rare ones) were not particularly targeted in array development or reliably imputed, and therefore not included in the analyses. We cannot rule out the possibility that a set of Nonetheless, the identified associations provide strong scientific rationale for future experimental studies to characterize the functional effects of these genetic variations.
In conclusion, our findings suggest an association between the Hippo pathway and ER+ breast cancer, with WWC1, LATS2, and CDH1
as possible genes driving this association. Further functional studies on genetic variants in these genes could help understand mechanisms of Hippo pathway in breast carcinogenesis, especially for women of
African ancestry who suffer a disproportionate burden of aggressive breast cancers with poor clinical outcomes for reasons that remain unexplained and understudied.
